Viridian Therapeutics, Inc. Common Stock (VRDN)
Viridian Therapeutics, Inc. (VRDN) is a biopharmaceutical company focused on developing innovative therapies for patients with rare and severe diseases. The company primarily concentrates on ophthalmic conditions, leveraging its expertise in antibody engineering and targeted biologics to address unmet medical needs.
Company News
Over 20 pharmaceutical companies are actively developing new treatments for Thyroid Eye Disease (TED), a serious autoimmune inflammatory condition affecting orbital tissues. The clinical trial pipeline is expanding with promising therapies targeting various mechanisms of the disease.
Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.
Viridian Therapeutics reported Q2 2025 results, highlighting progress in thyroid eye disease treatment with veligrotug, securing FDA Breakthrough Therapy Designation and a $70 million licensing deal with Kissei Pharmaceutical, while experiencing increased research expenses and net losses.
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 26.17% and 10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?